GSK India posted a strong Q1 FY27, with revenue growing 15% to ₹924 Cr.

Profit (PAT) jumped 24% to ₹253 Cr, achieving an EPS of ₹14.95. EBITDA also increased 17% to ₹293 Cr, driven by improved margins.

This robust performance stems from a successful portfolio transformation strategy and execution excellence.

Innovation, including new Oncology launches and Adult Vaccines like Shingrix (up 65%), contributed significantly to growth, now forming 7% of total sales.

Key General Medicines brands like Augmentin and T-Bact also saw competitive performance.

Strategically, GSK is focused on delivering growth across its portfolio, accelerating R&D, and simplifying operations through technology.

The company is actively building the adult immunization category and enhancing digital engagement with healthcare professionals.

Management commentary highlights consistent profitability improvement and a continued focus on strengthening the balance sheet.